Sayson, Jenny S.
HRN: 18-98-75 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/14/2023
CO-AMOXICLAV 625MG (TAB)
05/14/2023
05/21/2023
PO
1 Tab
BID
Multiple Soft Tissue Injury
Waiting Final Action
Indication: Prophylaxis Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes